Sig Brokerage LP Invests $452,000 in Eli Lilly and Company (NYSE:LLY)

Sig Brokerage LP bought a new position in Eli Lilly and Company (NYSE:LLY - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 585 shares of the company's stock, valued at approximately $452,000.

A number of other institutional investors have also recently modified their holdings of the stock. Silvercrest Asset Management Group LLC lifted its holdings in shares of Eli Lilly and Company by 1.9% during the fourth quarter. Silvercrest Asset Management Group LLC now owns 5,539 shares of the company's stock valued at $4,276,000 after purchasing an additional 103 shares in the last quarter. Rafferty Asset Management LLC lifted its holdings in shares of Eli Lilly and Company by 11.6% during the fourth quarter. Rafferty Asset Management LLC now owns 89,810 shares of the company's stock valued at $69,333,000 after purchasing an additional 9,327 shares in the last quarter. Raiffeisen Bank International AG bought a new position in shares of Eli Lilly and Company during the fourth quarter valued at $131,684,000. Ratan Capital Management LP lifted its holdings in shares of Eli Lilly and Company by 37.0% during the fourth quarter. Ratan Capital Management LP now owns 16,434 shares of the company's stock valued at $12,687,000 after purchasing an additional 4,434 shares in the last quarter. Finally, Redwood Investment Management LLC lifted its holdings in shares of Eli Lilly and Company by 42.7% during the fourth quarter. Redwood Investment Management LLC now owns 1,720 shares of the company's stock valued at $1,328,000 after purchasing an additional 515 shares in the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the business's stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the transaction, the chief accounting officer now owns 5,840 shares of the company's stock, valued at $4,778,521.60. The trade was a 14.62% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.13% of the stock is owned by company insiders.

Eli Lilly and Company Trading Up 2.4%

NYSE LLY opened at $732.40 on Friday. Eli Lilly and Company has a twelve month low of $677.09 and a twelve month high of $972.53. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. The stock has a market cap of $694.12 billion, a price-to-earnings ratio of 62.54, a PEG ratio of 1.40 and a beta of 0.48. The firm's 50 day moving average price is $799.17 and its two-hundred day moving average price is $807.15.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The company had revenue of $12.73 billion for the quarter, compared to analysts' expectations of $12.77 billion. During the same quarter in the prior year, the firm earned $2.58 earnings per share. The company's revenue was up 45.2% on a year-over-year basis. Equities analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be paid a $1.50 dividend. This represents a $6.00 annualized dividend and a dividend yield of 0.82%. The ex-dividend date is Friday, May 16th. Eli Lilly and Company's payout ratio is presently 48.82%.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. Morgan Stanley reissued an "overweight" rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. The Goldman Sachs Group raised Eli Lilly and Company from a "neutral" rating to a "buy" rating and dropped their target price for the stock from $892.00 to $888.00 in a research report on Tuesday, April 8th. StockNews.com raised Eli Lilly and Company from a "hold" rating to a "buy" rating in a research report on Friday, February 7th. UBS Group decreased their price objective on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating on the stock in a research note on Friday, May 2nd. Finally, Cantor Fitzgerald began coverage on Eli Lilly and Company in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 price objective on the stock. One research analyst has rated the stock with a sell rating, two have given a hold rating and eighteen have given a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $1,011.37.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.